Harmony Biosciences Holdings, Inc. (HRMY)
37.95
-0.32
(-0.84%)
USD |
NASDAQ |
Oct 16, 16:00
37.96
0.00 (0.00%)
After-Hours: 20:00
Harmony Biosciences Holdings Research and Development Expense (Annual) : 189.59M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 189.59M |
| December 31, 2024 | 145.82M |
| December 31, 2023 | 76.06M |
| December 31, 2022 | 70.89M |
| Date | Value |
|---|---|
| December 31, 2021 | 30.37M |
| December 31, 2020 | 19.45M |
| December 31, 2019 | 69.60M |
| December 31, 2018 | 12.37M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Liquidia Corp. | 38.45M |
| Pfizer Inc. | 10.25B |
| Bristol Myers Squibb Co. | 9.492B |
| Repligen Corp. | 51.31M |
| Johnson & Johnson | 14.83B |